Akums reports Q4 FY25 with 12.4% revenue growth

Akums invested Rs. 272 crore in capital expenditure during FY25

Lupin to present Phase 1 Data on LNP7457 at ASCO Annual Meeting 2025

Biocon Biologics receives MHRA, UK approval for biosimilar YESINTEK

YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde

Torrent Pharma reports Q4 FY25 PAT at Rs. 498 Cr

The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore

Lupin and SteinCares ink agreement for Ranibizumab in Latin America

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A

Gland Pharma Q4 FY25 PAT falls to Rs. 186.5 Cr

R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue

Divi's Laboratories inks manufacturing and supply agreement with global pharma company

The company expects meaningful revenue contribution from this long-term agreement

Glenmark Pharma reports Q4 FY25 PAT at Rs. 346.6 Cr

Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore

CPHI & PMEC China sees surge in international attendance

Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth

Strides Pharma Q4 net profit rises 5x to Rs. 113 Cr

For the full year FY25, net profit soared 12x to Rs 345 crore